The DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index.
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Open accessAbstract
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling of the bone marrow niche in a manner that promotes malignant over non-malignant hematopoiesis. This take-over of hematopoiesis by the malignant clone is hypothesized to include hyperactivation of inflammatory signaling and overproduction of inflammatory cytokines. In the Ph-negative MPNs, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET) to secondary myelofibrosis (MF), and the equivalent emergence of primary myelofibrosis (PMF). Bone marrow fibrosis itself is thought to be mediated heavily by the cytokine TGF-β, and possibly other cytokines produced as a result of hyperactivated JAK2 kinase in the malignant clone. MF also features extramedullary hematopoiesis and progression to bone marrow failure, both of which may be mediated in part by responses to cytokines. In MF, elevated levels of individual cytokines in plasma are adverse prognostic indicators: elevated IL-8/CXCL8, in particular, predicts risk of transformation of MF to secondary AML (sAML). Tumor necrosis factor (TNF, also known as TNFα), may underlie malignant clonal dominance, based on results from mouse models. Human PV and ET, as well as MF, harbor overproduction of multiple cytokines, above what is observed in normal aging, which can lead to cellular signaling abnormalities separate from those directly mediated by hyperactivated JAK2 or MPL kinases. Evidence that NFκB pathway signaling is frequently hyperactivated in a pan-hematopoietic pattern in MPNs, including in cells outside the malignant clone, emphasizes that MPNs are pan-hematopoietic diseases, which remodel the bone marrow milieu to favor persistence of the malignancy. Clinical evidence that JAK2 inhibition by ruxolitinib in MF neither reliably reduces malignant clonal burden nor eliminates cytokine elevations, suggests targeting cytokine mediated signaling as a therapeutic strategy, which is being pursued in new clinical trials. Greater knowledge of inflammatory pathophysiology in MPNs can therefore contribute to the development of more effective therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in contrast to the other myeloid progenitors, within the MkPs (wherein the CALR mutation exerts the greatest phenotypic effects due to the activation of the thrombopoietin receptor 21,54-57 ), the proliferative effects of IFNa were modest in the mutated cells compared to those at baseline ( Fig. 3e ), suggesting that the rate of cell cycle entry of the mutated cells was already near or at”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, in contrast to the other myeloid progenitors, within the MkPs (wherein the CALR mutation exerts the greatest phenotypic effects due to the activation of the thrombopoietin receptor 21,54-57 ), the proliferative effects of IFNa were modest in the mutated cells compared to those at baseline ( Fig. 3e ), suggesting that the rate of cell cycle entry of the mutated cells was already near or at”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
IFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovšek, S., Kantarjian, H. M., Mesa, R. A., Pardanani, A. D., Cortes, J. E., Thomas, D. A., Estrov, Z. E., Fridman, J. S., Bradley, E. C., Erickson‐Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,165
IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis
Vince, J. E., Wong, W. W.-L., Khan, N. R., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.037 · Cited by 1,076
Haematopoietic stem cell activity and interactions with the niche
Pinho, S., & Frenette, P. S. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0103-9 · Cited by 1,064
The molecular details of cytokine signaling via the JAK/STAT pathway
Morris, R., Kershaw, N. J., & Babon, J. J. (2018) · Protein Science · doi:10.1002/pro.3519 · Cited by 943
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891
Yoshihara, H., Arai, F., Hosokawa, K., Hagiwara, T., Takubo, K., Nakamura, Y., Gomei, Y., Iwasaki, H., Matsuoka, S., Miyamoto, K., et al. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.10.020 · Cited by 816
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A. D., Pereira, A., Finke, C. M., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 793
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
Guzmán, M. L., Neering, S. J., Upchurch, D., Grimes, B. A., Howard, D. S., Rizzieri, D. A., Luger, S. M., & Jordan, C. T. (2001) · Blood · doi:10.1182/blood.v98.8.2301 · Cited by 769
Ashburner, B. P., Westerheide, S. D., & Baldwin, A. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.7065-7077.2001 · Cited by 732
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Královics, R. (2016) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 716
Pietras, E. M., Mirantes-Barbeito, C., Fong, S., Loeffler, D., Kovtonyuk, L. V., Zhang, S., Lakshminarasimhan, R., Chin, C. P., Techner, J.-M., Will, B., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3346 · Cited by 689
Campbell, P. J., Scott, L. M., Buck, G. A. N., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A. M., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 651
Tefferi, A., Vaidya, R., Caramazza, D., Finke, C. M., Lasho, T. L., & Pardanani, A. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9490 · Cited by 608
Effect of Mutation Order on Myeloproliferative Neoplasms
Ortmann, C. A., Kent, D. G., Nangalia, J., Silber, Y., Wedge, D. C., Grinfeld, J., Baxter, E. J., Massie, C. E., Papaemmanuil, E., Menon, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412098 · Cited by 607
Critical Role of Thrombopoietin in Maintaining Adult Quiescent Hematopoietic Stem Cells
Qian, H., Buza-Vidas, N., Hyland, C. D., Jensen, C. T., Antonchuk, J., Månsson, R., Thorén, L., Ekblom, M., Alexander, W. S., & Jacobsen, S. E. W. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.10.008 · Cited by 600
Kiladjian, J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 582
Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis
Petersen, S. L., Wang, L., Yalcin-Chin, A., Li, L., Peyton, M., Minna, J. D., Harran, P. G., & Wang, X. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.029 · Cited by 579
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2018) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 529
Signal transduction by tumor necrosis factor receptors
Cabal‐Hierro, L., & Lazo, P. S. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.02.006 · Cited by 456
for the COMFORT-I investigators, Verstovšek, S., Mesa, R. A., Gotlib, J. R., Gupta, V. K., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0417-z · Cited by 446
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014) · Nature · doi:10.1038/nature13383 · Cited by 444
Quintás‐Cardama, A., Kantarjian, H. M., Manshouri, T., Luthra, R., Estrov, Z. E., Pierce, S. A., Richie, M. A., Borthakur, G. M., Konopleva, M. Y., Cortes, J. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Myeloproliferative neoplasms and thrombosis
Barbui, T., Finazzi, G., & Falanga, A. (2013) · Blood · doi:10.1182/blood-2013-03-460154 · Cited by 415
Spivak, J. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1406186 · Cited by 404
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Rumi, E., Pietra, D., Pascutto, C., Guglielmelli, P., Martínez‐Trillos, A., Casetti, I. C., Colomer, D., Pieri, L., Pratcorona, M., Rotunno, G., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578435 · Cited by 397
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A. D., Gotlib, J. R., Jamieson, C. H. M., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J. S., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 397
TNF-α Coordinates Hematopoietic Stem Cell Survival and Myeloid Regeneration
Yamashita, M., & Passegué, E. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.05.019 · Cited by 387
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V., Bogani, C., Ferrini, P. R., Rambaldi, A., Guerini, V., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404854 · Cited by 369
Zhao, J. L., Ma, C., O’Connell, R. M., Mehta, A., DiLoreto, R., Heath, J. R., & Baltimore, D. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.01.007 · Cited by 339
Hasselbalch, H. C. (2012) · Blood · doi:10.1182/blood-2011-11-394775 · Cited by 331
Oh, S. T., Simonds, E. F., Jones, C. D., Hale, M. B., Goltsev, Y., Gibbs, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P., & Gotlib, J. R. (2010) · Blood · doi:10.1182/blood-2010-02-270108 · Cited by 330
Self-citationMilhollen, M. A., Traore, T., Duffy, J., Thomas, M. P., Berger, A., Dang, L., Dick, L. R., Garnsey, J., Koenig, E. M., Langston, S., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272567 · Cited by 327
Kleppe, M., Kwak, M., Koppikar, P., Riester, M., Keller, M., Bastian, L., Hricik, T., Bhagwat, N., McKenney, A. S., Papalexi, E., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0736 · Cited by 325
Guglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A. D., Zoi, K., Reiter, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.76 · Cited by 311
Verstovsek, S., Gotlib, J., Mesa, R. A., Vannucchi, A. M., Kiladjian, J.-J., Cervantes, F., Harrison, C. N., Paquette, R., Sun, W., Naim, A., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0527-7 · Cited by 305
Rodriguez-Meira, A., Buck, G., Clark, S.-A., Povinelli, B. J., Alcolea, V., Louka, E., McGowan, S., Hamblin, A., Sousos, N., Barkas, N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.01.009 · Cited by 305
Lin, J. J., Milhollen, M. A., Smith, P. G., Narayanan, U., & Dutta, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2062 · Cited by 297
Tet2 restrains inflammatory gene expression in macrophages
Cull, A. H., Snetsinger, B., Buckstein, R., Wells, R. A., & Rauh, M. J. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.08.001 · Cited by 295
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pardanani, A. D., & Tefferi, A. (2008) · Leukemia · doi:10.1038/leu.2008.113 · Cited by 293
Elf, S., Abdelfattah, N. S., Chen, E., Perales-Patón, J., Rosen, E. A., Ko, A., Peisker, F., Florescu, N., Giannini, S., Wolach, O., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1434 · Cited by 293
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
Fleischman, A. G., Aichberger, K. J., Luty, S. B., Bumm, T. G. P., Petersen, C. L., Doratotaj, S., Vasudevan, K. B., LaTocha, D. H., Yang, F., Press, R. D., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348144 · Cited by 292
Kristinsson, S. Y., Björkholm, M., Hultcrantz, M. L., Derolf, Å. R., Landgren, O., & Goldin, L. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8540 · Cited by 289
Schneider, R. K., Mullally, A., Dugourd, A. J. F., Peisker, F., Hoogenboezem, R. M., van Strien, P. M. H., Bindels, E. M., Heckl, D., Büsche, G., Fleck, D., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.03.008 · Cited by 281
Kleppe, M., Koche, R., Zou, L., van Galen, P., Hill, C. E., Dong, L., De Groote, S., Papalexi, E., Hanasoge Somasundara, A. V., Cordner, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.009 · Cited by 279
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Swords, R. T., Kelly, K. R., Smith, P. G., Garnsey, J., Mahalingam, D., Medina, E. C., Oberheu, K., Padmanabhan, S., O'Dwyer, M. E., Nawrocki, S. T., et al. (2010) · Blood · doi:10.1182/blood-2009-11-254862 · Cited by 277
Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270
Tefferi, A., Lasho, T. L., Huang, J., Finke, C. M., Mesa, R. A., Li, C. Y., Wu, W., Hanson, C. A., & Pardanani, A. D. (2008) · Leukemia · doi:10.1038/sj.leu.2405097 · Cited by 252
Cerquozzi, S., & Tefferi, A. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.95 · Cited by 249
Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5429-5444.2005 · Cited by 247
Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., Maris, M. B., Hua, Z., Blakemore, S. J., Faessel, H. M., Sedarati, F., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13323 · Cited by 238
Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice
Chagraoui, H., Komura, E., Tulliez, M., Giraudier, S., Vainchenker, W., & Wendling, F. (2002) · Blood · doi:10.1182/blood-2002-04-1133 · Cited by 238
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A. D., Laborde, R. R., Lasho, T. L., Finke, C. M., Begna, K. H., Al‐Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A. A., Kowalski, M. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 236
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity
Kagoya, Y., Yoshimi, A., Kataoka, K., Nakagawa, M. M., Kumano, K., Arai, S., Kobayashi, H., Saito, T., Iwakura, Y., & Kurokawa, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68101 · Cited by 233
An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis
Abegunde, S. O., Buckstein, R., Wells, R. A., & Rauh, M. J. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2017.11.002 · Cited by 230
Gaither, A., PORTER, D. A., Yao, Y., Borawski, J. A., Yang, G., Donovan, J., Sage, D. R., Slisz, J. K., Tran, M., Straub, C. S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-5173 · Cited by 225
Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo‐Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., et al. (2009) · Blood · doi:10.1182/blood-2009-04-216044 · Cited by 216
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
Hasselbalch, H. C., & Bjørn, M. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/102476 · Cited by 213
Pardanani, A. D., Lasho, T. L., Smith, G. D., Burns, C. J., Fantino, E., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.50 · Cited by 210
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
Swords, R. T., Coutre, S. E., Maris, M. B., Zeidner, J. F., Foran, J. M., Cruz, J. C., Erba, H. P., Berdeja, J. G., Tam, W., Vardhanabhuti, S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-805895 · Cited by 203
Understanding early TLR signaling through the Myddosome
Balka, K. R., & Nardo, D. D. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-096r · Cited by 201
Autoimmunity and the risk of myeloproliferative neoplasms
Kristinsson, S. Y., Landgren, O., Samuelsson, J., Björkholm, M., & Goldin, L. R. (2010) · Haematologica · doi:10.3324/haematol.2009.020412 · Cited by 200
Pronk, C. J., Veiby, O. P., Bryder, D., & Jacobsen, S. E. W. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110752 · Cited by 199
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199
Barbui, T., Carobbio, A., Finazzi, G., Vannucchi, A. M., Barosi, G., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Salmoiraghi, S., Zilio, P., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031070 · Cited by 199
Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., Russo, L., Guerini, V., & Barbui, T. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.01.053 · Cited by 194
Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling
Chen, E., Beer, P. A., Godfrey, A. L., Ortmann, C. A., Li, J., Costa‐Pereira, A. P., Ingle, C., Dermitzakis, E. T., Campbell, P. J., & Green, A. R. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.013 · Cited by 185
The bone marrow microenvironment – Home of the leukemic blasts
Shafat, M. S., Gnaneswaran, B., Bowles, K. M., & Rushworth, S. A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.03.004 · Cited by 185
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Schinke, C., Giricz, O., Li, W., Shastri, A., Gordon, S. A. K., Barreyro, L., Bhagat, T. D., Bhattacharyya, S., Ramachandra, N., Bartenstein, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621631 · Cited by 183
Pardanani, A. D., Lasho, T. L., Finke, C. M., Oh, S. T., Gotlib, J. R., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.163 · Cited by 182
Self-citationKoschmieder, S., Mughal, T. I., Hasselbalch, H. C., Barosi, G., Valent, P., Kiladjian, J., Jeryczynski, G., Gisslinger, H., Jutzi, J. S., Pahl, H. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.12 · Cited by 179
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison, C. N., Mead, A. J., Panchal, A., Fox, S., Yap, C., Gbandi, E., Houlton, A. E., Alimam, S., Ewing, J. C., Wood, M. E., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785790 · Cited by 179
Delhommeau, F., Dupont, S., Tonetti, C., Massé, A., Godin, I., Couedic, J. P. L., Debili, N., Saulnier, P., Casadevall, N., Vainchenker, W., et al. (2006) · Blood · doi:10.1182/blood-2006-03-007146 · Cited by 177
Verger, E., Cassinat, B., Chauveau, A., Dosquet, C., Giraudier, S., Schlageter, M., Ianotto, J., Yassin, M. A., Al-Dewik, N. I. E., Carillo, S., et al. (2015) · Blood · doi:10.1182/blood-2015-07-659060 · Cited by 176
Deininger, M., Radich, J., Burn, T. C., Huber, R., Paranagama, D., & Verstovsek, S. (2015) · Blood · doi:10.1182/blood-2015-03-635235 · Cited by 173
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
Verstovšek, S., Manshouri, T., Pilling, D., Bueso-Ramos, C., Newberry, K. J., Prijić, S., Knez, L., Božinović, K., Harris, D., Spaeth, E. L., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160283 · Cited by 164
Milhollen, M. A., Narayanan, U., Soucy, T. A., Veiby, P. O., Smith, P. G., & Amidon, B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2122 · Cited by 161
Targeting NF-κB in hematologic malignancies
Braun, T., Carvalho, G., Fabre, C., Grosjean, J., Fenaux, P., & Kroemer, G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401874 · Cited by 158
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Wen, Q. J., Yang, Q., Goldenson, B., Malinge, S., Lasho, T. L., Schneider, R. K., Breyfogle, L. J., Schultz, R. F., Gilles, L., Koppikar, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3995 · Cited by 157
Endothelial transplantation rejuvenates aged hematopoietic stem cell function
Poulos, M. G., Ramalingam, P., Gutkin, M. C., Llanos, P., Gilleran, K., Rabbany, S. Y., & Butler, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93940 · Cited by 153
Vaidya, R., Gangat, N., Jimma, T., Finke, C. M., Lasho, T. L., Pardanani, A., & Tefferi, A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23295 · Cited by 149
Larsen, T. S., Pallisgaard, N., Møller, M. B., & Hasselbalch, H. C. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00960.x · Cited by 145
Fisher, D. A. C., Miner, C. A., Engle, E. K., Hu, H., Collins, T. B., Zhou, A. W., Allen, M. J., Malkova, O. N., & Oh, S. T. (2019) · Leukemia · doi:10.1038/s41375-019-0379-y · Cited by 143
Self-citationBirkenkamp, K. U., Geugien, M., Schepers, H., Westra, J. M., Lemmink, H. H., & Vellenga, E. (2003) · Leukemia · doi:10.1038/sj.leu.2403145 · Cited by 143
S100A9 induces differentiation of acute myeloid leukemia cells through TLR4
Laouedj, M., Tardif, M. R., Gil, L., Raquil, M.-A., Lachhab, A., Pelletier, M., Tessier, P. A., & Barabé, F. (2017) · Blood · doi:10.1182/blood-2016-09-738005 · Cited by 142
TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells
Li, J., Sejas, D. P., Zhang, X., Qiu, Y., Nattamai, K., Rani, R., Rathbun, K. R., Geiger, H., Williams, D. A., Bagby, G. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31772 · Cited by 141
Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression
Handschick, K., Beuerlein, K., Jurida, L., Bartkuhn, M., Müller, H., Soelch, J., Weber, A., Dittrich-Breiholz, O., Schneider, H., Scharfe, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.002 · Cited by 141
Panteli, K. E., Hatzimichael, E. C., Bouranta, P. K., Katsaraki, A., Seferiadis, K. I., Stebbing, J., & Bourantas, K. L. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05674.x · Cited by 138
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
Kiladjian, J., Giraudier, S., & Cassinat, B. (2015) · Leukemia · doi:10.1038/leu.2015.326 · Cited by 133
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
Pourcelot, E., Trocme, C., Mondet, J., Bailly, S., Toussaint, B., & Mossuz, P. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.01.006 · Cited by 132
Intra- and Intercellular Quality Control Mechanisms of Mitochondria
Kiriyama, Y., & Nochi, H. (2017) · Cells · doi:10.3390/cells7010001 · Cited by 131
Genome reading by the NF-κB transcription factors
Mulero, M. C., Wang, V. Y., Huxford, T., & Ghosh, G. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz739 · Cited by 130
Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
Geyer, H. L., Dueck, A. C., Scherber, R. M., & Mesa, R. A. (2015) · Mediators of Inflammation · doi:10.1155/2015/284706 · Cited by 129
Smac Mimetics and TNFα: A Dangerous Liaison?
Wu, H., Tschopp, J., & Lin, S. (2007) · Cell · doi:10.1016/j.cell.2007.10.042 · Cited by 128
Norfo, R., Zini, R., Pennucci, V., Bianchi, E., Salati, S., Guglielmelli, P., Bogani, C., Fanelli, T., Mannarelli, C., Rosti, V., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544197 · Cited by 128
Stivala, S., Codilupi, T., Brkić, Š., Baerenwaldt, A., Ghosh, N., Hao-Shen, H., Dirnhofer, S., Dettmer, M. S., Simillion, C., Kaufmann, B. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci98785 · Cited by 127
Wang, A., & Zhong, H. (2018) · Hematology · doi:10.1080/10245332.2018.1486064 · Cited by 123
The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies
Craver, B. M., Alaoui, K. E., Scherber, R. M., & Fleischman, A. G. (2018) · Cancers · doi:10.3390/cancers10040104 · Cited by 120
RelA repression of RelB activity induces selective gene activation downstream of TNF receptors
Jacque, É., Tchénio, T., Piton, G., Roméo, P., & Baud, V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507342102 · Cited by 117
Vannucchi, A. M., Bianchi, L., Paoletti, F., Pancrazzi, A., Torre, E., Nishikawa, M., Zingariello, M., Baldassarre, A. D., Rana, R. A., Lorenzini, R., et al. (2005) · Blood · doi:10.1182/blood-2004-04-1320 · Cited by 115
Fisher, D. A. C., Malkova, O., Engle, E. K., Miner, C. A., Fulbright, M. C., Behbehani, G. K., Collins, T. B., Bandyopadhyay, S., Zhou, A. W., Nolan, G. P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.377 · Cited by 113
Self-citationMascarenhas, J. O., Talpaz, M., Gupta, V. K., Foltz, L. M., Savona, M. R., PAQUETTE, R. L., Turner, A. R., Coughlin, P., Winton, E. F., Burn, T. C., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151126 · Cited by 109
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1502524 · Cited by 108
Hasselbalch, H. C., & Holmström, M. O. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0700-2 · Cited by 106
Blank, J. L., Liu, X. J., Cosmopoulos, K., Bouck, D. C., Garcia, K., Bernard, H., Tayber, O., Hather, G., Liu, R., Narayanan, U., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1729 · Cited by 103
Does ruxolitinib prolong the survival of patients with myelofibrosis?
Cervantes, F., & Pereira, A. (2016) · Blood · doi:10.1182/blood-2016-11-731604 · Cited by 101
MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors
Knorr, K. L. B., Schneider, P., Meng, X. W., Dai, H., Smith, B. D., Hess, A. D., Karp, J. E., & Kaufmann, S. H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.74 · Cited by 100
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Gupta, V. K., Mesa, R. A., Deininger, M. W., Rivera, C. E., Sirhan, S., Brachmann, C. B., Collins, H., Kawashima, J., Xin, Y., & Verstovšek, S. (2016) · Haematologica · doi:10.3324/haematol.2016.148924 · Cited by 100
Jacquelin, S., Straube, J., Cooper, L., Vu, T., Song, A., Bywater, M., Baxter, E., Heidecker, M., Wackrow, B., Porter, A., et al. (2018) · Blood · doi:10.1182/blood-2018-04-846220 · Cited by 99
Constitutive NF-κB activation in AML: Causes and treatment strategies
Bosman, M. C. J., Schuringa, J. J., & Vellenga, E. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.001 · Cited by 95
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML
Volk, A. G., Li, J., Xin, J., You, D., Zhang, J., Liu, X., Xiao, Y., Breslin, P., Li, Z., Wei, W., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130990 · Cited by 94
Buss, H., Handschick, K., Jurrmann, N., Pekkonen, P., Beuerlein, K., Müller, H., Wait, R., Saklatvala, J., Ojala, P. M., Schmitz, M. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051847 · Cited by 92
MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia
Abdul-Aziz, A. M., Shafat, M. S., Mehta, T. K., Palma, F. D., Lawes, M. J., Rushworth, S. A., & Bowles, K. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1095 · Cited by 89
Kent, D. G., Li, J., Tanna, H., Fink, J., Kirschner, K., Pask, D. C., Silber, Y., Hamilton, T. L., Sneade, R., Simons, B. D., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001576 · Cited by 87
Steensma, D. P., Mesa, R. A., Li, C., Gray, L. A., & Tefferi, A. (2002) · Blood · doi:10.1182/blood.v99.6.2252 · Cited by 87
on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators, Vannucchi, A. M., Rotunno, G., Bartalucci, N., Raugei, G., Carrai, V., Balliu, M., Mannarelli, C., Pacilli, A., Calabresi, L., et al. (2014) · Leukemia · doi:10.1038/leu.2014.100 · Cited by 86
Kvasnicka, H. M., Thiele, J., Bueso-Ramos, C., Sun, W. Y., Cortes, J. E., Kantarjian, H. M., & Verstovšek, S. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0585-5 · Cited by 85
Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature
Ustwani, O. A., Ford, L. A., Sait, S. N. J., Block, A. M. W., Barcos, M. P., Vigil, C. E., Griffiths, E. A., Thompson, J. E., Wang, E. S., Ambrus, J. L., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.04.007 · Cited by 84
Khalife, J., Radomska, H. S., Santhanam, R., Huang, X., Neviani, P., Saultz, J. N., Wang, H., Wu, Y.-Z., Alachkar, H., Anghelina, M. I., et al. (2015) · Leukemia · doi:10.1038/leu.2015.106 · Cited by 83
Inflammatory bone marrow microenvironment
Leimkühler, N. B., & Schneider, R. K. (2019) · Hematology · doi:10.1182/hematology.2019000045 · Cited by 82
Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB
Kuo, H.-P., Wang, Z., Lee, D., 岩崎, 正., Duque‐Afonso, J., Wong, S. H. K., Lin, C.-H., Figueroa, M. E., Su, J., Lemischka, I. R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.019 · Cited by 80
Komura, E., Tonetti, C., Penard‐Lacronique, V., Chagraoui, H., Lacout, C., Couedic, J. P. L., Rameau, P., Debili, N., Vainchenker, W., & Giraudier, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2339 · Cited by 78
Ramalingam, P., Poulos, M. G., Lazzari, E., Gutkin, M. C., Lopez, D., Kloss, C. C., Crowley, M. J., Katsnelson, L., Freire, A. G., Greenblatt, M. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14478-8 · Cited by 78
Inflammatory Reactive Oxygen Species-Mediated Hemopoietic Suppression in Fancc-Deficient Mice
Sejas, D. P., Rani, R., Qiu, Y., Zhang, X., Fagerlie, S. R., Nakano, H., Williams, D. A., & Pang, Q. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5277 · Cited by 74
Verstovšek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rumi, E., Gattoni, E., Pieri, L., Zhen, H., Granier, M., Assad, A., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765032 · Cited by 71
Tubi, L. Q., Nunes, S. C., Brancalion, A., Breatta, E. D., Manni, S., Mandato, E., Zaffino, F., Macaccaro, P., Carrino, M., Gianesin, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.209 · Cited by 69
Autoimmunity and hematologic malignancies: associations and mechanisms
Martin, D. N., Mikhail, I. S., & Landgren, O. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902780677 · Cited by 65
Lussana, F., Carobbio, A., Salmoiraghi, S., Guglielmelli, P., Vannucchi, A. M., Bottazzi, B., Leone, R., Mantovani, A., Barbui, T., & Rambaldi, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0425-z · Cited by 62
Boissinot, M., Cleyrat, C., Vilaine, M., Jacques, Y., Corre, I., & Hermouet, S. (2010) · Oncogene · doi:10.1038/onc.2010.479 · Cited by 62
Barbui, T., Carobbio, A., Finazzi, G., Guglielmelli, P., Salmoiraghi, S., Rosti, V., Rambaldi, A., Vannucchi, A. M., & Barosi, G. (2013) · Leukemia · doi:10.1038/leu.2013.207 · Cited by 61
Gibbs, K. D., Gilbert, P. M., Sachs, K., Zhao, F., Blau, H. M., Weissman, I. L., Nolan, G. P., & Majeti, R. (2011) · Blood · doi:10.1182/blood-2010-07-298232 · Cited by 58
Heterogeneity in myeloproliferative neoplasms: Causes and consequences
O’Sullivan, J., & Mead, A. J. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.11.007 · Cited by 58
Zhou, L., Chen, S., Zhang, Y., Kmieciak, M., Leng, Y., Li, L., Lin, H., Rizzo, K., Dumur, C. I., Ferreira‐Gonzalez, A., et al. (2016) · Blood · doi:10.1182/blood-2015-06-653717 · Cited by 57
Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm
Fleischman, A. G. (2015) · Mediators of Inflammation · doi:10.1155/2015/606819 · Cited by 56
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
Heaton, W. L., Senina, A. V., Pomicter, A. D., Salama, M. E., Clair, P. M., Yan, D., Bell, R. N., Gililland, J. M., Prchal, J. T., O’Hare, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0131-z · Cited by 56
Williams, N., Lee, J., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A. H., Godfrey, A. L., Green, A. R., Campbell, P. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.09.374710 · Cited by 56
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
Cacemiro, M. D. C., Cominal, J. G., Tognon, R., Nunes, N. D. S., Simões, B. P., Figueiredo-Pontes, L. L. D., Catto, L. F. B., Traina, F., Souto, E. X., Zambuzi, F. A., et al. (2018) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2017.12.003 · Cited by 55
Lack of the ubiquitin-editing enzyme A20 results in loss of hematopoietic stem cell quiescence
Nakagawa, M. M., Thummar, K., Mandelbaum, J., Pasqualucci, L., & Rathinam, C. V. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20132544 · Cited by 54
Efficacy of ALK5 inhibition in myelofibrosis
Yue, L., Bartenstein, M., Zhao, W., Ho, W., Han, Y., Murdun, C., Mailloux, A. W., Zhang, L., Wang, X., Budhathoki, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90932 · Cited by 53
Chen, E., Ahn, J. S., Massie, C. E., Clynes, D., Godfrey, A. L., Li, J., Park, H. J., Nangalia, J., Silber, Y., Mullally, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401873111 · Cited by 53
Barosi, G., Klersy, C., Villani, L., Bonetti, E., Catarsi, P., Poletto, V., Campanelli, R., Impera, S. S., Latagliata, R., Viarengo, G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.45 · Cited by 53
Wagner‐Ballon, O., Pisani, D. F., Gastinne, T., Tulliez, M., Chaligné, R., Lacout, C., Aurade, F., Villeval, J., Gonin, P., Vainchenker, W., et al. (2007) · Blood · doi:10.1182/blood-2006-10-054502 · Cited by 52
JAK2 Mutation-Related Disease and Thrombosis
Guglielmelli, P., & Vannucchi, A. M. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1343890 · Cited by 51
Verstovšek, S., Savona, M. R., Mesa, R. A., Dong, H., Maltzman, J. D., Sharma, S., Silverman, J. A., Oh, S. T., & Gotlib, J. R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14501 · Cited by 51
Self-citationNakagawa, M. M., Chen, H. A., & Rathinam, C. V. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00143 · Cited by 51
PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study
Verstovšek, S., Hasserjian, R. P., Pozdnyakova, O., Veletić, I., Mesa, R. A., Foltz, L. M., Mascarenhas, J. O., Ritchie, E. K., Palmer, J. M., Silver, R. T., et al. (2018) · Blood · doi:10.1182/blood-2018-99-115362 · Cited by 48
Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies
Kennedy, R., & Klein, U. (2018) · Cells · doi:10.3390/cells7110189 · Cited by 46
Nakagawa, M. M., & Rathinam, C. V. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.071 · Cited by 46
CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks
Uras, I. Z., Maurer, B., Nivarthi, H., Jodl, P., Kollmann, K., Prchal‐Murphy, M., Feenstra, J. D. M., Zojer, M., Lagger, S., Grausenburger, R., et al. (2019) · Blood · doi:10.1182/blood-2018-08-872648 · Cited by 46
Stetka, J., Vyhlidalova, P., Lanikova, L., Kořalková, P., Gurský, J., Hlusi, A., Flódr, P., Hubáčková, S., Bártek, J., Hodný, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0813-7 · Cited by 43
Swords, R. T., Watts, J. M., Erba, H. P., Altman, J. K., Maris, M. B., Anwer, F., Hua, Z.-C., Stein, H., Faessel, H. M., Sedarati, F., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.1 · Cited by 42
Barosi, G., Massa, M., Campanelli, R., Fois, G., Catarsi, P., Viarengo, G., Villani, L., Poletto, V., Bosoni, T., Magrini, U., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.06.004 · Cited by 41
Xiao, Y., Li, H., Zhang, J., Volk, A. G., Zhang, S., Wei, W., Zhang, S., Breslin, P., & Zhang, J. (2011) · Blood · doi:10.1182/blood-2011-06-359448 · Cited by 39
Myeloproliferative Neoplasm Animal Models
Mullally, A., Lane, S., Brumme, K. M., & Ebert, B. L. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.07.007 · Cited by 39
Grosjean-Raillard, J., Adès, L., Boehrer, S., Tailler, M., Fabre, C., Braun, T., de Botton, S., Israël, A., Fenaux, P., & Kroemer, G. (2008) · APOPTOSIS · doi:10.1007/s10495-008-0243-4 · Cited by 39
Czuczman, N. M., Barth, M. J., Gu, J. J., Neppalli, V. T., Mavis, C. K., Frys, S., Hu, Q., Liu, S., Klener, P., Vočková, P., et al. (2015) · Blood · doi:10.1182/blood-2015-04-640920 · Cited by 37
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
Craver, B. M., Nguyen, T. K., Nguyen, J. M., Nguyen, H., Huynh, C., Morse, S. J., & Fleischman, A. G. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0157-6 · Cited by 37
Grosjean-Raillard, J., Adès, L., Boehrer, S., Tailler, M., Fabre, C., Braun, T., de Botton, S., Israël, A., Fenaux, P., & Kroemer, G. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1154-9 · Cited by 34
Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia
Xiu, Y., Dong, Q.-Z., Li, Q.-C., Li, F.-Y., Borcherding, N., Zhang, W.-Z., Boyce, B., Xue, H.-H., & Zhao, C. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.055 · Cited by 33
SMAC mimetics as potential cancer therapeutics in myeloid malignancies
Boddu, P. C., Carter, B. Z., Verstovšek, S., & Pemmaraju, N. (2019) · British Journal of Haematology · doi:10.1111/bjh.15829 · Cited by 33
Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
Swierczek, S. I., Yoon, D., Bellanné‐Chantelot, C., Kim, S. J., Saint‐Martin, C., Delhommeau, F., NAJMAN, A., & Prchal, J. T. (2011) · Haematologica · doi:10.3324/haematol.2010.029678 · Cited by 29
Pardanani, A. D., Begna, K. H., Finke, C. M., Lasho, T. L., & Tefferi, A. (2011) · American Journal of Hematology · doi:10.1002/ajh.21972 · Cited by 28
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
Wolenski, F. S., Fisher, C. D., Sano, T., Wyllie, S. D., Cicia, L. A., Gallacher, M., Baker, R. A., Kirby, P. J., & Senn, J. J. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.34 · Cited by 27
Bortezomib therapy in myelofibrosis: a phase II clinical trial
Mesa, R. A., Verstovšek, S., Rivera, C. E., Pardanani, A. D., Hussein, K., Lasho, T. L., Wu, W., & Tefferi, A. (2008) · Leukemia · doi:10.1038/leu.2008.32 · Cited by 26
Nagamachi, A., Nakata, Y., Ueda, T., Yamasaki, N., Ebihara, Y., Tsuji, K., Honda, Z.-I., Takubo, K., Suda, T., Oda, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087425 · Cited by 25
Wagner‐Ballon, O., Chagraoui, H., Prina, E., Tulliez, M., Milon, G., Raslová, H., Villeval, J., Vainchenker, W., & Giraudier, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6425 · Cited by 25
Nuclear factor k B is activated in myelodysplastic bone marrow cells.
Sanz, C., Richard, C., Prósper, F., & Fernandez-Luna, J. L. (2002) · PubMed · Cited by 24
Leclerc, G. M., Zheng, S., Leclerc, G. J., DeSalvo, J., Swords, R. T., & Barredo, J. C. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.007 · Cited by 24
Serum beta‐2‐microglobulin, TNF‐α and interleukins in myeloproliferative disorders
Bourantas, K. L., Hatzimichael, E. C., Makis, A., Chaidos, A., Kapsali, E., Tsiara, S., & Mavridis, A. K. (1999) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1999.tb01845.x · Cited by 23
Williams, N., Lee, J., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A. H., Godfrey, A. L., Green, A. R., Campbell, P. J., et al. (2020) · Blood · doi:10.1182/blood-2020-143813 · Cited by 22
Grießhammer, M., & Sadjadian, P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1404574 · Cited by 22
Liu, X., Jiang, Y., Wu, J., Zhang, W., Liang, Y., Jia, L., Yu, J., Jeong, L. S., & Li, L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.122 · Cited by 19
Barosi, G., Gattoni, E., Guglielmelli, P., Campanelli, R., Facchetti, F., Fisogni, S., Goldberg, J. D., Marchioli, R., Hoffman, R., & Vannucchi, A. M. (2010) · American Journal of Hematology · doi:10.1002/ajh.21754 · Cited by 19
Pemmaraju, N., Carter, B. Z., Kantarjian, H. M., Cortes, J. E., Bose, P., Kadia, T. M., Garcia‐Manero, G., Bueso-Ramos, C., Dinardo, C. D., Bledsoe, S. D., et al. (2019) · Blood · doi:10.1182/blood-2019-130046 · Cited by 19
Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
Kalota, A., Jeschke, G. R., Carroll, M. P., & Hexner, E. O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1907 · Cited by 16
Grosjean, J., Adès, L., Boehrer, S., Fenaux, P., & Kroemer, G. (2007) · Blood · doi:10.1182/blood.v110.11.2434.2434 · Cited by 15
A20 deficiency in multipotent progenitors perturbs quiescence of hematopoietic stem cells
Nakagawa, M. M., Davis, H., & Rathinam, C. V. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.10.020 · Cited by 14
Zhou, A. W., Afzal, A., & Oh, S. T. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0401-2 · Cited by 14
Self-citationFowles, J. S., How, J., Allen, M. J., & Oh, S. T. (2019) · Leukemia · doi:10.1038/s41375-018-0349-9 · Cited by 13
Self-citationBarabanshikova, M. V., Dubina, I. A., Lapin, S. V., Morozova, E. V., Vlasova, J. J., Ivanova, M. O., Moiseev, I., & Afanasyev, B. V. (2017) · Oncology Research and Treatment · doi:10.1159/000477253 · Cited by 12
Kawatani (1997) · International Journal of Hematology · doi:10.1016/s0925-5710(96)00554-3 · Cited by 11
Nakagawa, M. M., & Rathinam, C. V. (2019) · Scientific Reports · doi:10.1038/s41598-019-49038-8 · Cited by 11
Mondello, P., Mirto, C. D., Cuzzocrea, S., Arrigo, C., Mian, M., & Pitini, V. V. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.027 · Cited by 10
Prognostication in MF: From CBC to cytogenetics to molecular markers
Zhou, A. W., & Oh, S. T. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.07.008 · Cited by 9
Self-citationIshikawa, G., Fujiwara, N., Hirschfield, H., Varricchio, L., Hoshida, Y., Barosi, G., Rosti, V., Padilla, M. L., Mazzarini, M., Friedman, S. L., et al. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.10.001 · Cited by 9
Barosi, G., Campanelli, R., Catarsi, P., AMICI, M. D., Abbà, C., Viarengo, G., Villani, L., Gale, R. P., Rosti, V., & Massa, M. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106319 · Cited by 8
Egeren, D. V., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S. H., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I. A., et al. (2020) · Blood · doi:10.1182/blood-2020-141643 · Cited by 5
Stengel, A., Baer, C. R., Walter, W., Meggendorfer, M., Kern, W., Haferlach, T., & Haferlach, C. (2020) · Blood · doi:10.1182/blood-2020-136288 · Cited by 3
Flagged first, then by citations
1 of the 196 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Hasselbalch, 2015, Ruxolitinib Versus Standard Therapy for the Treatment of Polycythemia Vera, N Engl J Med, 372, 1670, 10.1056/NEJMc1502524 · DOI · Paper page
Cited by
Sorted by citations
Adès, L., Girshova, L., Doronin, V. A., Díez-Campelo, M., Valcárcel, D., Kambhampati, S., Viniou, N.-A., Woszczyk, D., De Paz Arias, R., Symeonidis, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007334 · Cited by 130
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 103
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms
Melo‐Cardenas, J., Bezavada, L., Crawford, J. C., Gurbuxani, S. K., Cotton, A., Kang, G., Gossett, J. M., Marinaccio, C., Weinberg, R. S., Hoffman, R., et al. (2022) · Blood · doi:10.1182/blood.2022017326 · Cited by 69
Defining disease modification in myelofibrosis in the era of targeted therapy
Pemmaraju, N., Verstovšek, S., Mesa, R. A., Gupta, V. K., Garcia, J. S., Scandura, J. M., Oh, S. T., Passamonti, F., Döhner, K., & Mead, A. J. (2022) · Cancer · doi:10.1002/cncr.34205 · Cited by 64
Self-citationMalignant JAK-signaling: at the interface of inflammation and malignant transformation
Perner, F., Pahl, H. L., Zeiser, R., & Heidel, F. H. (2025) · Leukemia · doi:10.1038/s41375-025-02569-8 · Cited by 71
Metadata
- Authors
- Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Oh, Stephen Tracy
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-06-01
- Volume
- 12
- Pages
- 683401-683401
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC8204249
- OpenAlex
- W3167008187
- Cited by
- 115
- References
- 196
- Citations by year
- 2026: 21 · 2025: 20 · 2024: 23 · 2023: 19 · 2022: 27 · 2021: 4
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR073752)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- myeloproliferative neoplasms, inflammatory cytokines, bone marrow microenvironment, clonal dominance, secondary myelofibrosis, polycythemia vera, essential thrombocythemia, primary myelofibrosis, TGF-beta, JAK2, NF-κB signaling, IL-8/CXCL8, TNF-α, ruxolitinib, cytokine-targeted therapy, extramedullary hematopoiesis, bone marrow failure, myeloid neoplasms
- MeSH terms
- Age Factors, Cell Transformation, Neoplastic, Disease Susceptibility, Humans, Models, Biological, Myeloproliferative Disorders, Signal Transduction, Biomarkers, Cytokines, Inflammation Mediators, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
